State of the Art: Oral GH Secretagogues and Their Clinical Future

Comprehensive review of orally active GH secretagogues including their pharmacology, clinical trial results, and therapeutic potential across GH deficiency, aging, and catabolic states.

Ghigo, E et al.·Annals of medicine·1998·Moderate EvidenceReview
RPEP-00462ReviewModerate Evidence1998RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Oral GH secretagogues effectively increase GH and IGF-1 through a specific receptor, with clinical potential spanning GH deficiency, aging, and catabolic states, though their optimal therapeutic role remained to be defined.

Key Numbers

How They Did This

Comprehensive review of published preclinical and clinical data on oral GH secretagogues.

Why This Research Matters

This review represented the most complete clinical assessment of oral GH secretagogues available at the time, helping define where these agents fit in endocrine therapeutics and identifying which clinical applications showed the most promise.

The Bigger Picture

The development of oral GH secretagogues represented a potential paradigm shift in treating GH-related disorders. Instead of daily GH injections, patients could potentially take a pill that stimulates natural GH production. This review captured the field's optimism while noting that optimal clinical applications were still being defined.

What This Study Doesn't Tell Us

1998 review — clinical trial database was still developing. Long-term outcome data not available. The therapeutic niche for oral GH secretagogues versus GH replacement was not yet resolved.

Questions This Raises

  • ?Will oral GH secretagogues replace GH injections for any indications?
  • ?What are the long-term metabolic effects of chronic GH secretagogue use?
  • ?Can oral GH secretagogues improve outcomes in critically ill catabolic patients?

Trust & Context

Key Stat:
Effective oral GH stimulation Multiple oral compounds demonstrated consistent GH and IGF-1 elevation in clinical trials across diverse patient populations
Evidence Grade:
Comprehensive clinical review in Annals of Medicine. Synthesizes substantial preclinical and clinical evidence but reflects early-stage clinical development.
Study Age:
Published in 1998, this review captures the peak of pharmaceutical interest in oral GH secretagogues. Many compounds discussed did not ultimately reach market, though MK-677 remains widely studied.
Original Title:
Orally active growth hormone secretagogues: state of the art and clinical perspectives.
Published In:
Annals of medicine, 30(2), 159-68 (1998)
Authors:
Ghigo, E(14), Arvat, E(6), Camanni, F(3)
Database ID:
RPEP-00462

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

What makes a GH secretagogue 'orally active'?

Most peptide-based GH releasers are destroyed by digestion and must be injected. Orally active secretagogues are non-peptide molecules that survive digestion and absorb through the gut, allowing them to be taken as pills.

Did oral GH secretagogues ever become approved medications?

Despite promising clinical trial results, most oral GH secretagogues from this era did not achieve regulatory approval for GH-related indications. However, MK-677 continues to be studied in clinical trials for various conditions.

Read More on RethinkPeptides

Cite This Study

RPEP-00462·https://rethinkpeptides.com/research/RPEP-00462

APA

Ghigo, E; Arvat, E; Camanni, F. (1998). Orally active growth hormone secretagogues: state of the art and clinical perspectives.. Annals of medicine, 30(2), 159-68.

MLA

Ghigo, E, et al. "Orally active growth hormone secretagogues: state of the art and clinical perspectives.." Annals of medicine, 1998.

RethinkPeptides

RethinkPeptides Research Database. "Orally active growth hormone secretagogues: state of the art..." RPEP-00462. Retrieved from https://rethinkpeptides.com/research/ghigo-1998-orally-active-growth-hormone

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.